Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

5

Revenue 2017

Avastin

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Avastin was produced by Roche.

Roche files Tecentriq/Avastin combo in liver cancer

Roche files Tecentriq/Avastin combo in liver cancer

Roche has filed Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as a first-line treatment for unresectable hepatocellular carcinoma (HCC) – the most common form of liver cancer. ... Patients received PD-L1 inhibitor Tecentriq plus

AZ’s Imfinzi scores orphan drug status in liver cancer

AZ’s Imfinzi scores orphan drug status in liver cancer Also looking to make gains in the HCC market is Roche, with its own immunotherapy combination of Tecentriq (atezolizumab) and its older cancer drug Avastin (bevacizumab)   recently showing a benefit as

Roche’s Tecentriq combo scores in first-line melanoma

Roche’s Tecentriq combo scores in first-line melanoma Roche also has plans to file a Tecentriq/Avastin combination treatment for liver cancer.

Lynparza cleared for first-line ovarian cancer use in China

Lynparza cleared for first-line ovarian cancer use in China However, AZ and MSD are not resting on their laurels just yet, as they are also exploring the use of Lynparza in combination with Avastin (bevacizumab) as a first-line maintenance

Mylan, Biocon’s Herceptin biosimilar launched in US

Mylan, Biocon’s Herceptin biosimilar launched in US Alongside Herceptin, this includes Avastin (bevacizumab) and MabThera (rituximab) which are also under threat from new biosimilar launches.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Purple Agency

An Integrated Marketing Communications Agency with a passion for Intelligent Strategy, Compelling Creativity and Professional Delivery....

Latest intelligence

David Atkins
A snapshot of Congenica
PME talks to CEO David Atkins...
Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...

Infographics